Advertisement
New Zealand markets closed
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NZD/USD

    0.5970
    -0.0006 (-0.10%)
     
  • NZD/EUR

    0.5534
    +0.0001 (+0.02%)
     
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD

    2,254.80
    +16.40 (+0.73%)
     
  • NASDAQ

    18,254.69
    -26.15 (-0.14%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,807.37
    +47.29 (+0.12%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • NZD/JPY

    90.3370
    -0.0560 (-0.06%)
     

Pacific Edge awarded patent in Japan

The world’s second largest single biomedical market, Japan, has awarded Pacific Edge a patent for its colorectal cancer prognostic technology. Pacific Edge Chief Executive Officer David Darling says the issue of the patent in Japan is a significant step for the Company by providing intellectual property protection in the country where colorectal cancer is the most prevalent cancer.

"Currently our focus is on accelerating the roll-out of the Company’s first commercial molecular diagnostic test, Cxbladder-detect, in the USA, the world’s largest health care market. As milestones are attained there, the opportunity to launch the Cxbladder system into other markets and bring to market further developments of our intellectual property, such as our colorectal cancer technology, become attractive.

"We are on track to launch our second product, Cxbladder-triage, into the NZ market late this year. This is an exciting time for Pacific Edge."

Colorectal cancer is overall the most prevalent cancer in Japan, the second highest in men and third highest in women. Its incidence in Japan has increased dramatically over the last 30 years which has been attributed to changing lifestyles and diets.

ADVERTISEMENT

Pacific Edge’s colorectal cancer prognostic technology is targeted to enables the detection of aggressive cancer in patients already diagnosed with colorectal cancer. This prognostic test in development, already branded Cxcolorectal, is expected to provide clinicians with a significantly improved opportunity to determine the aggressiveness of Stage II and Stage III colorectal cancer. The test results will enable physicians to predict progression and provide patients with a more specific treatment following surgery. Pacific Edge’s colorectal cancer prognostic gene signature is in late stage development and on completion will become another commercial product for the Company, joining the Cx family as Cxcolorectal. Pacific Edge Chief Executive Officer David Darling says the issue of the patent in Japan is a significant step for the Company by providing us intellectual property protection in this large market.

"Currently our focus is on accelerating the roll-out of the Company’s first commercial molecular diagnostic test, Cxbladder-detect, in the USA, the world’s largest health care market. As milestones are attained there, the opportunity to launch the Cxbladder system into other markets and bring to market further developments of our intellectual property, such as Cxcolorectal, become attractive. We are on track to launch our second product, Cxbladder-triage, into the NZ market late this year. An exciting time for us all"

Pacific Edge announced the successful completion of a European clinical trial for the prognostic gene signature for colorectal cancer in June 2010 when the results were released at the annual scientific meeting of the American Society for Clinical Oncology (ASCO), by Signature Diagnostics. The positive results from this international study demonstrate the capability of the Company’s colorectal cancer technology in distinguishing between patients at high-risk or low-risk of disease progression.

Presently, patients with Stage II disease are generally not treated with adjuvant chemotherapy as it is not possible to identify the subset of patients who will have aggressive disease. In the five major European countries, the USA and Japan, approximately 430,000 individuals are diagnosed with colorectal cancer every year. Of these those diagnosed cases approximately 280,000 patients are diagnosed with Stage II and Stage III progressions of the cancer. Approximately 30% of the patients with Stage II and roughly 50% of those with Stage III experience disease progression including distant metastasis of the liver and lung or local recurrence within three to five years after surgery. If the cancer spreads to distant organs, the five-year survival rate for these patients is approximately 8% making the early detection of those patients with an aggressive disease a significant medical opportunity for clinicians and patients. Cxcolorectal will provide clinicians with a valuable tool to help identify these those patients at greatest risk who will then be able to be more appropriately targeted for adjuvant chemotherapy in addition to surgery.